Skip to content

Study · In vitro (cell-free) · 1991

2 results

Two insulin-like growth factor (IGF)-binding proteins are responsible for the selective affinity for IGF-II of cerebrospinal fluid binding proteins.

Roghani M, Lassarre C, Zapf J, Povoa G, Binoux M

The Journal of clinical endocrinology and metabolism1 Sept 1991Cited by 57 (Europe PMC)

PMID1714916 (opens in a new tab)DOI10.1210/jcem-73-3-658 (opens in a new tab)PepBankPUB-01714916
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cell-free)Activity measurement

    In purified protein assays, des-(1-3)-IGF-I failed to bind cerebrospinal fluid binding proteins.

    In plain wordsIn lab tests, des-(1-3)-IGF-I did not bind the cerebrospinal fluid binding proteins.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    Not applicableCSF binding protein binding
    Study

    humann: not reported in source

    Purified IGF-binding proteins
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Des-(1-3)-IGF-I failed to bind to the CSF BPs, but bound to IGFBP-1, although with a 40-fold weaker affinity than IGF-I.
    1 context sentence
    Summary · context
    Competitive binding studies were performed using preparations of human recombinant IGF (rhIGF-I, rhIGF-II, and their labeled homologs) and the truncated variant form of IGF-I, rh-Des-(1-3)-IGF-I.
  2. 02LabIn vitro (cell-free)Activity measurement

    In purified protein assays, des-(1-3)-IGF-I bound IGFBP-1 with 40-fold weaker affinity than IGF-I.

    In plain wordsIn lab tests, des-(1-3)-IGF-I bound IGFBP-1 less strongly than IGF-I.

    Peptide
    IGF-1 DES (des(1-3)IGF-I)
    Outcome
    DecreaseIGFBP-1 binding affinity
    Study

    humann: not reported in source

    Purified IGF-binding proteins
    Comparator
    IGF-I
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    Relative affinity reduction
    40 fold
    versus IGF-I

    Source sentences

    Summary
    Des-(1-3)-IGF-I failed to bind to the CSF BPs, but bound to IGFBP-1, although with a 40-fold weaker affinity than IGF-I.
    1 context sentence
    Summary · context
    Competitive binding studies were performed using preparations of human recombinant IGF (rhIGF-I, rhIGF-II, and their labeled homologs) and the truncated variant form of IGF-I, rh-Des-(1-3)-IGF-I.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 13:52 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.